Zhongxin Finance, May 11th. On the morning of the 11th, in response to the public opinion that the nucleic acid results of Runda Medical showed "false positives", Runda Medical issued an announcement saying that the company has asked Zhongke Laboratory to initiate an internal self-regulation of the relevant situation. Investigate and cooperate with relevant departments.

If there are relevant circumstances that need to be clarified or explained, the company will promptly perform its information disclosure obligations.

  Previously, relevant reports mentioned that the company's subsidiary Shanghai Zhongke Runda Medical Laboratory Co., Ltd. had tested positive for some samples during nucleic acid screening in Huangpu District, Shanghai, but related cases were tested after entering the makeshift hospital. In the case of a negative result, the accuracy of the nucleic acid test data of the Zhongke Laboratory is questioned accordingly.

  Runda Medical said that Zhongke Laboratory is a wholly-owned company of Shanghai Zhongke Runda Precision Medical Inspection Co., Ltd., which holds 48.43% of the company's shares.

At present, all business lines of the company are operating normally.

  On the 11th, the Shanghai Stock Exchange issued a supervisory work letter to Runda Medical, putting forward work requirements on matters related to media coverage.